

# Somatic mutations in children with *GATA2*-associated myelodysplastic syndrome who lack other features of *GATA2* deficiency

Kevin E. Fisher,<sup>1,2</sup> Amy P. Hsu,<sup>3</sup> Christopher L. Williams,<sup>2</sup> Hadi Sayeed,<sup>1</sup> Brian Y. Merritt,<sup>1</sup> M. Tarek Elghetany,<sup>1,2</sup> Steven M. Holland,<sup>3</sup> Alison A. Bertuch,<sup>2</sup> and Maria Monica Gramatges<sup>2</sup>

<sup>1</sup>Department of Pathology & Immunology, and <sup>2</sup>Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX; and <sup>3</sup>Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

## Key Points

- Children with primary MDS should be tested for *GATA2* mutations, regardless of karyotype, family history, or features of *GATA2* deficiency.
- Screening children with *GATA2*-MDS for somatic mutations may reveal mutations predictive of clinical outcomes.

Approximately 10% of children with primary myelodysplastic syndrome (MDS) have germ line *GATA2* mutations, leading to the proposal that all children with primary MDS and certain cytogenetic findings, including monosomy 7, be tested for germ line *GATA2* mutations regardless of family history or other clinical features associated with *GATA2* deficiency. In adults with familial *GATA2*-MDS, those with somatic mutations in *ASXL1* experience rapid disease progression to acute myeloid leukemia (AML) and poor prognosis after stem cell transplantation; however, the prevalence of somatic mutations in primary pediatric *GATA2*-MDS is unclear. Here, we studied a cohort of 8 pediatric patients with MDS and lacking additional *GATA2*-associated clinical features or significant family history and identified heterozygous germ line *GATA2* mutations in 5 patients, including 1 with a normal karyotype. For those with *GATA2*-MDS, we screened for somatic mutations in genes with prognostic relevance in AML/MDS, using a targeted next-generation sequencing panel. Although no somatic mutations in *ASXL1* were observed, somatic mutations were found in *RUNX1*, *SETBP1*, *IKZF1*, and *CRLF2*. One subject with deleterious mutations in *RUNX1*, *SETBP1*, and *IKZF1* rapidly progressed to AML with disease that was refractory to treatment. Our findings confirm the importance of *GATA2* testing in primary pediatric MDS, even in the absence of other clinical features of *GATA2* deficiency. Further, similar to what has been observed in adults with *GATA2*-MDS, somatic mutations with potential prognostic effect occur in children with MDS associated with mutations in *GATA2*.

## Introduction

Myelodysplastic syndrome (MDS) is a heterogeneous disorder manifesting as ineffective hematopoiesis with risk for infection, hemorrhage, and evolution to acute myeloid leukemia (AML). MDS is rare in childhood, but risk is increased in the setting of certain inherited bone marrow failure syndromes (IBMFS)<sup>1-5</sup> or after cancer treatment that includes radiation or specific chemotherapy.<sup>6</sup> Recent genomic analyses of children and young adults with idiopathic MDS or IBMFS revealed a proportion with germ line mutations in *GATA2*, a gene that encodes a zinc finger transcription factor involved in hematopoiesis and lymphatic development.<sup>7,8</sup> In primary pediatric MDS, heterozygous *GATA2* mutations are the most common germ line defect, occurring in 7% of cases and frequently associated with monosomy 7.<sup>9</sup>

A spectrum of conditions falls under the umbrella of *GATA2* deficiency-associated phenotypes, all the result of germ line mutations in *GATA2*. Among these are monocytopenia and mycobacterial infection (MonoMAC syndrome),<sup>10-12</sup> dendritic cell, monocyte, B and NK cell lymphoid deficiency,<sup>13</sup> primary lymphedema with myelodysplasia progressing to AML (Emberger syndrome),<sup>12,14</sup> and a subset of

familial MDS.<sup>15</sup> The extent to which children with *GATA2*-MDS may present without other clinical features suggestive of *GATA2*-deficiency is unknown.

Somatic mutations that affect disease prognosis are relatively common in adults with MDS, most often involving *TET2*, *SF3B1*, *ASXL1*, *SRSF2*, *DNMT3A*, and *RUNX1*.<sup>16,17</sup> Somatic mutations in *ASXL1* are also described in familial *GATA2*-MDS,<sup>18,19</sup> correlating with an increased risk for myeloid transformation.<sup>20</sup> In a small cohort of children with *GATA2*-MDS and a family history of MonoMac or Emberger syndromes, mutations in additional driver genes were noted, including *ASXL1*, *RUNX1*, *SETBP1*, and *NRAS*.<sup>21</sup>

The primary objective of this study was to determine whether *GATA2* mutations would be readily identified in children diagnosed with MDS, but without features suggestive of *GATA2* deficiency, such as those described by Spinner et al.<sup>22</sup> We screened 8 children with primary MDS lacking past medical or family history suggestive of *GATA2* deficiency for *GATA2* mutations, and found 5 to have germ line mutations, emphasizing that MDS may be the presenting feature of *GATA2* deficiency in children. In addition, we show that among children with *GATA2*-MDS, next-generation sequencing (NGS) may detect somatic mutations in genes related to AML/MDS disease progression.

## Methods

### Subject population

We queried 2 institutional review board–approved Baylor College of Medicine studies (H-3342 and H-17698) for subjects diagnosed with MDS. The objective of these protocols is to enroll subjects (primarily children at our clinical site, Texas Children's Hospital) who are undergoing bone marrow aspiration for suspected or known malignancy (H-3342) or bone marrow failure disorder (H-17698). All subjects enrolled have provided written informed consent to participate in this research. Among the MDS cases identified, we excluded those who lacked tissue samples; were treatment-related; were previously diagnosed with an IBMFS or severe aplastic anemia; had a history of other manifestations of *GATA2*-deficiency, such as certain viral infections or *Mycobacterium avium* intracellular infections (history of limited, localized warts allowed); or had a known or suspected family history of a *GATA2*-associated disorder. Additional clinical and laboratory information was obtained from medical records. The MDS diagnosis of refractory cytopenia of childhood (RCC), based on World Health Organization criteria,<sup>23</sup> was confirmed by independent pathology review.

### *GATA2* analysis

Initial sequence analysis of *GATA2* consisted of bidirectional sequencing of DNA from peripheral blood cells, bone marrow, or buccal swab, and included upstream and intronic regulatory regions using previously described primers.<sup>10</sup> *GATA2* single nucleotide variants were interrogated for germ line status using targeted sequencing on DNA isolated from mouthwash samples or buccal swabs obtained after hematopoietic stem cell transplantation (HSCT). For cases with mouthwash samples post-HSCT, PCR products were Topo TA cloned (Thermo Fisher Scientific) and sequenced to detect the germ line mutant allele among the wild-type allele present in contaminating donor-derived lymphocytes. Array comparative genomic hybridization was applied to peripheral blood mononuclear cell at diagnosis and fibroblast DNA for 1 subject as a clinical evaluation (Baylor Medical Genetics Laboratories).

### Testing for somatic mutations

A custom-designed, targeted Agilent SureSelect QXT NGS panel was used to sequence promoter, exonic, and intronic gene regions relevant to

pediatric MDS/AML. The sequencing panel design is provided in supplemental Table 1. For subjects with *GATA2* mutations and available diagnostic (4 patients) or relapse (1 patient) bone marrow samples, NGS libraries were prepared from extracted DNA. All samples were multiplexed and sequenced on a MiSeq flow cell in paired-end mode. Read alignment to the reference human genome (GRCh37), variant calling, and annotation were performed using NextGENe and Oncotator software. Variants passing defined depth of coverage (>100×) and variant allele fraction (>0.05) filters were queried against publicly available databases and reviewed for pathogenic significance.

## Results

Among subjects enrolled on the above-described study protocols, 15 were identified with MDS. Eight subjects remained after exclusion of cases lacking tissue samples (2 patients), cases with treatment-related MDS (1 patient), or a previous diagnosis of an IBMFS (3 patients) or severe aplastic anemia (1 patient), and cases characterized by infections associated with *GATA2* deficiency (0 patients) or known or suspected family history of a *GATA2*-associated disorder (0 patients).

Germ line *GATA2* mutations were detected in 5 of these 8 presumed primary MDS cases (Table 1). In 2 subjects (BMF41 and BMF67), sequencing identified previously described *GATA2* splice site mutations that abolish the splice acceptor for intron 4 (mRNA transcript NM\_032638.4): 1 with c.1018-1G>A<sup>10</sup> and 1 with c.1018-2A>C, albeit with a unique nucleotide substitution.<sup>9,21</sup> A third subject (BMF109) had a novel *GATA2* splice site mutation, c.1144-1G>C, which alters the intron 5 splice acceptor (in the same isoform noted earlier). A fourth subject (BMF129) harbored a nucleotide deletion in exon 3 (isoform as noted earlier), c.599delG, leading to a frameshift p.G200VfsX18<sup>9</sup> (see supplemental Figure 1 for sequencing chromatograms). In all 4 of these cases, the *GATA2* mutation identified was determined to be germ line by targeted sequencing of either mouthwash or buccal samples obtained post-HSCT, when the subjects were in clinical remission. In the fifth subject (BMF52), a large deletion was suspected, given that the *GATA2* sequence analysis of pre-BMT peripheral blood mononuclear cell DNA showed absence of heterozygosity at each of 6 polymorphic sites within the *GATA2* sequence with minor allele frequencies  $\geq 0.20$ . Clinical array comparative genomic hybridization testing revealed a 3.1- to 3.3-Mb heterozygous deletion encompassing the *GATA2* locus and contiguous genes, which was determined germ line by analysis of DNA from cultured skin fibroblasts (Figure 1). Familial testing for *GATA2* mutations revealed no parental mutations in 2 cases for which both parents were available for testing (BMF52 and BMF129), nor in the remaining 3 cases for which only 1 parent was available for testing.

All 5 *GATA2*-MDS subjects had bone marrow pathology consistent with RCC. Four patients demonstrated monosomy 7 on routine karyotyping, and 1 subject had a normal karyotype and a negative MDS FISH panel for 5q-, 7-, 7q-, trisomy 8, and 20q-. Other common morphologic and laboratory features of the *GATA2*-MDS cohort included megakaryocytic and erythroid dysplasia (n = 5), hypocellular bone marrow aspirates for age (n = 4), monocytopenia (n = 3), decreased granulocytes (n = 3), and absence of reticuline fibrosis in all cases.

Next-generation sequencing of detected mutations in genes associated with poor AML/MDS prognosis was noted in 3 of 5 *GATA2*-MDS subjects (Table 1). These included 5 unique mutations in

**Table 1. Patient characteristics and mutation data in a pediatric *GATA2*-MDS cohort**

Case	Age at Dx/sex	Dx and cytogenetics	Germ line <i>GATA2</i> mutation	Sample source for <i>GATA2</i> analysis	Somatic mutations	VAF (%)	Relapse	No. of HSCTs	Progress to AML?	Vital status	Length of FU (days)
BMF41	9/F	RCC with monosomy 7	c.1018-1G>A	PB, LCL (pre-HSCT)	<i>RUNX1</i> c.593A>G, p.D198G	29.8	Yes	3	Yes	Dead	1460
BMF67	15/M	RCC with NK	c.1018-2A>C	PB, LCL (pre-HSCT)	None	-	No	1	No	Alive	1871
BMF109*	5/F	RCC with monosomy 7	c.1144-1G>C	BM (relapse)	None†	†	Yes	2	No	Alive	3687
BMF129	8/F	RCC with monosomy 7	c.599delG, p.G200VfsX18	MW (post-HSCT)	None	-	No	1	No	Alive	469
BMF52	12/M	RCC with monosomy 7	3.1-3.3 Mb het del encompassing <i>GATA2</i>	PBMC (pre-HSCT)	<i>CRLF2</i> c.188A>G, p.N63S	58.0	Yes	3	Yes	Alive	1814


RefSeq IDs: *GATA2*, NM\_032638.4; *RUNX1*, NM\_001754.4; *SETBP1*, NM\_015559.2; *IKZF1*, NM\_006060.4; *CRLF2*, NM\_022148.2.  
 AML, acute myeloid leukemia; BM, bone marrow; BS, buccal swab; Dx, diagnosis; F, female; FU, follow-up; het del, heterozygous deletion; HSCT, hematopoietic stem cell transplant; LCL, lymphoblastoid cell line; M, male; MW, mouthwash; NK, normal karyotype; No., number; PB, peripheral blood; PBMC, peripheral blood mononuclear cells; RCC, refractory cytopenia of childhood; SF, skin fibroblast; VAF, variant allele frequency.  
 \*No diagnostic sample available. Pathologic features and acquired mutation testing assessed on first relapse sample.  
 †BMF109 was noted to have a mutation in *RUNX1* c.167T>C, p.L56S at a variant allele frequency of 30.0% in the relapsed BM sample. This mutation was also found in the MW sample obtained after HSCT, and was therefore considered germ line (supplemental Figure 2).

*RUNX1*, *SETBP1*, *IKZF1*, and *CRLF2*. Mutations were present in the diagnostic bone marrow sample for all subjects save 1, BMF109, who presented to our institution in relapse after initial diagnosis and treatment at an outside institution. One of the *RUNX1* variants, p.L56P, which was detected in BMF109, was determined to be germ line after detection of the mutation by targeted sequencing of DNA from a mouthwash sample post-HSCT (supplemental Figure 2), consistent with its reported minor allele frequency of 1.6% in the Exome Aggregation Consortium database (accessed November 2016). In contrast, the *RUNX1* p.D198G mutation detected in BMF41 was absent in an LCL-derived sample obtained from this patient, and was therefore somatic (supplemental Figure 2). Of the 5 *GATA2*-MDS subjects, then, 2 were found to have somatic mutations in AML-driver genes.

## Discussion

We detected germ line *GATA2* mutations in 5 of 8 pediatric primary MDS cases, despite the absence of other clinical features suggestive of *GATA2* deficiency. Although limited by the constraints of a retrospective case review, our observations are consistent with recent studies suggesting *GATA2* analysis is critical to the diagnostic workup of pediatric MDS.<sup>9</sup> As expected, monosomy 7, prevalent in *GATA2*-MDS,<sup>12,15</sup> was noted in 4 of 5 cases. The *GATA2* mutations detected included 3 splice site mutations, a frameshift mutation, and a large heterozygous deletion, which was initially suspected by the absence of heterozygosity across the several polymorphic sites within the *GATA2* locus. These classes are in line with the frameshift, nonsense, and splice site *GATA2* mutations that account for approximately half of reported germ line alterations in *GATA2*-MDS.<sup>9</sup> Heterozygous *GATA2* gene deletions, however, are rare in primary *GATA2*-MDS.<sup>9</sup> Limited reports of germ line large, de novo deletions spanning *GATA2* and neighboring genes have been noted in association with MDS, but in patients with developmental and neurological deficits, as well as dysmorphic features.<sup>12</sup> In contrast, our case lacked any discernable phenotype and had normal neurocognitive function. The absence of relevant family history in our cohort, as well as the failure to detect parental mutations, suggests the mutations we observed arose de novo, which has been shown to be the case in approximately two-thirds of *GATA2*-MDS.<sup>24</sup> However, only 1 parent was available for testing in 3 of 5 cases, so we cannot exclude the possibility that the nontested parent was a carrier.

The routine assessment of morphologic, flow cytometric, and cytogenetic findings in bone marrow aspirates can be suggestive of *GATA2* deficiency in a subset of patients with MDS. The constellation of bone marrow hypocellularity for age and atypical megakaryocytes, particularly the presence of separate nuclear lobes, abnormal granulocytic maturation, and reticulin fibrosis, along with peripheral blood B-cell and NK-cell lymphopenia and monocytopenia, is indicative of the diagnosis.<sup>22,25</sup> In our *GATA2*-MDS cohort, dysplastic megakaryocytes and bone marrow hypocellularity were common to all diagnostic marrows. However, peripheral blood monocytopenia and abnormal granulocytic maturation were not consistent features, and there was no appreciable fibrosis in any of the bone marrows examined. Notably, for 1 patient (BMF129), the pathologist recommended germ line *GATA2* sequencing at the time of diagnosis because of the combination of trilineage dysplasia, characteristic megakaryocytic dysplasia, and profound monocytopenia and neutropenia. Our findings highlight the evolving spectrum of morphology and laboratory findings in *GATA2*-MDS, particularly



**Figure 1. Heterozygous deletion encompassing *GATA2* in a subject with primary MDS and lacking additional features of *GATA2* deficiency.** Array comparative genomic hybridization of fibroblast DNA (courtesy of Baylor Medical Genetics Laboratories), demonstrating the 3.1- to 3.3-Mb deletion encompassing *GATA2* identified in BMF52. The GRCh37/hg19 genomic location of *GATA2* is chromosome 3, nucleotides 128198265 through 128212030. Red dots represent copy number losses, green dots represent copy number gains, and orange dots represent known polymorphisms. A subset of additional genes within the deleted segment is shown.

for those who lack *GATA2*-associated clinical features or significant family history.

We observed somatic mutations in several genes associated with AML disease progression (Table 1). Somatic mutations in *SETBP1*, including p.G870S, are independent and poor prognostic indicators in adult AML and MDS.<sup>26</sup> Somatic mutations in *RUNX1* are also common in adult MDS/AML,<sup>27</sup> and the p.D198G substitution observed in our cohort is described in cases of MDS progressing to AML.<sup>28</sup> Large *IKZF1* focal deletions are rare, but recurrent, events in pediatric AML, in conjunction with monosomy 7.<sup>29</sup> Although *CRLF2* mutations are well-characterized in relapsed B-acute lymphoblastic leukemia,<sup>30</sup> their clinical significance in AML/MDS is unclear. Our study was not powered to detect the prognostic effect of somatic mutations on disease course, although the 2 cases with somatic mutations experienced relapse or disease progression. The subject with the *CRLF2* mutation developed AML after a second HSCT, but remains in remission after a third HSCT. The subject harboring concomitant mutations in *SETBP1*, *RUNX1*, and *IKZF1* experienced an aggressive clinical course marked by multiple disease relapses and progression to AML despite receiving 3 HSCTs, ultimately dying of refractory disease.

Our results confirm the importance of *GATA2* sequencing in the evaluation of primary pediatric MDS, as the identification of a

germ line mutation has crucial implications for related HSCT donor selection and genetic counseling. Moreover, *GATA2* sequencing reported as “no mutation identified” should prompt deletion analysis, as absence of neurodevelopmental findings does not preclude a *GATA2* gene deletion. Last, similar to observations in adult and familial *GATA2*-MDS, we provide evidence that the acquisition of potential driver mutations in genes predictive of AML/MDS disease progression occur in children with primary *GATA2*-MDS. Therefore, testing for these mutations using a disease-specific NGS panel may detect prognostic mutations predictive of disease clinical course.

## Acknowledgments

*GATA2* sequence analysis was performed by GeneDx for 1 patient.

This work was supported, in part, by a Cancer Prevention Research Institute of Texas grant (RP129976) (A.A.B.).

## Authorship

Contribution: K.E.F. drafted the manuscript and analyzed the NG sequencing data for somatic mutations; A.P.H. performed *GATA2* sequence analysis and edited the manuscript; C.L.W. prepared samples, performed *GATA2* sequencing, and drafted the methods; H.S. performed NG sequencing for somatic mutations and drafted

the methods; B.Y.M. provided pathological review and edited the manuscript; M.T.E. provided pathological review and edited the manuscript; S.M.H. assisted in study design and data analysis and edited the manuscript; A.A.B. assisted in study design and data analysis and revised/edited the manuscript; and M.M.G. assisted with study design, extracted and analyzed medical data, and revised/edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: M.M.G., 0000-0002-0947-104X.

Correspondence: Maria Monica Gramatges, Texas Children's Hospital, Feigin Center, 1102 Bates, Suite 1200, Houston, TX 77030; e-mail: gramatge@bcm.edu.

## References

1. Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. *Blood*. 2012;119(16):3815-3819.
2. Rosenberg PS, Alter BP, Bolyard AA, et al; Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. *Blood*. 2006;107(12):4628-4635.
3. Smith OP, Hann IM, Chessells JM, Reeves BR, Milla P. Haematological abnormalities in Shwachman-Diamond syndrome. *Br J Haematol*. 1996;94(2):279-284.
4. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. *Blood*. 1994;84(5):1650-1655.
5. Owen CJ, Toze CL, Koochin A, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. *Blood*. 2008;112(12):4639-4645.
6. Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. *Semin Oncol*. 2013;40(6):666-675.
7. Zhang MY, Keel SB, Walsh T, et al. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. *Haematologica*. 2015;100(1):42-48.
8. Keel SB, Scott A, Sanchez-Bonilla M, et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. *Haematologica*. 2016;101(11):1343-1350.
9. Wlodarski MW, Hirabayashi S, Pastor V, et al; EWOG-MDS. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. *Blood*. 2016;127(11):1387-1397, quiz 1518.
10. Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. *Blood*. 2011;118(10):2653-2655.
11. Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. *Blood*. 2013;121(19):3830-3837.
12. Kazenwadel J, Secker GA, Liu YJ, et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. *Blood*. 2012;119(5):1283-1291.
13. Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. *Blood*. 2011;118(10):2656-2658.
14. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). *Nat Genet*. 2011;43(10):929-931.
15. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. *Nat Genet*. 2011;43(10):1012-1017.
16. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia*. 2014;28(2):241-247.
17. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*. 2013;122(22):3616-3627, quiz 3699.
18. Churpek JE, Pyrtel K, Kanchi KL, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. *Blood*. 2015;126(22):2484-2490.
19. Bödör C, Renneville A, Smith M, et al. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. *Haematologica*. 2012;97(6):890-894.
20. West RR, Hsu AP, Holland SM, Cuellar-Rodriguez J, Hickstein DD. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. *Haematologica*. 2014;99(2):276-281.
21. Wang X, Muramatsu H, Okuno Y, et al. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies. *Haematologica*. 2015;100(10):e398-e401.
22. Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. *Blood*. 2014;123(6):809-821.
23. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol 2. Geneva: World Health Organization; 2008

24. Collin M, Dickinson R, Bigley V. Haematopoietic and immune defects associated with GATA2 mutation. *Br J Haematol*. 2015;169(2):173-187.
25. Ganapathi KA, Townsley DM, Hsu AP, et al. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. *Blood*. 2015;125(1):56-70.
26. Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. *Nat Genet*. 2013;45(8):942-946.
27. Della Porta MG, Galli A, Bacigalupo A, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. *J Clin Oncol*. 2016;34(30):3627-3637.
28. Pellagatti A, Boulwood J. The molecular pathogenesis of the myelodysplastic syndromes. *Eur J Haematol*. 2015;95(1):3-15.
29. de Rooij JD, Beuling E, van den Heuvel-Eibrink MM, et al. Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia. *Haematologica*. 2015;100(9):1151-1159.
30. Ma X, Edmonson M, Yergeau D, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. *Nat Commun*. 2015;6:6604.